NASDAQ:MITO Stealth BioTherapeutics (MITO) Stock Price, News & Analysis → Fidelity, Bezos, Goldman Bet Big on Tiny Biotech (From Behind the Markets) (Ad) Free MITO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.32▼$0.3250-Day Range$0.31▼$0.3252-Week Range$0.16▼$1.03VolumeN/AAverage Volume946,105 shsMarket Capitalization$23.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Stealth BioTherapeutics alerts: Email Address Ad Behind the MarketsBREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.Discover the name and ticker of this $2 stock here >>> About Stealth BioTherapeutics Stock (NASDAQ:MITO)Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.Read More Ad Behind the MarketsBREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.Discover the name and ticker of this $2 stock here >>> MITO Stock News HeadlinesMay 7, 2024 | prnewswire.comSTEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATIONMay 6, 2024 | prnewswire.comStealth BioTherapeutics to Present at JMP Citizens Life Sciences ConferenceMay 8, 2024 | Behind the Markets (Ad)Fidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.April 17, 2024 | money.usnews.comBolt Biotherapeutics IncApril 8, 2024 | prnewswire.comSTEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROMEFebruary 22, 2024 | wsj.comSonnet BioTherapeutics Holdings Inc.February 9, 2024 | investing.comIovance Biotherapeutics Inc (IOVA)November 23, 2023 | morningstar.comBarinthus Biotherapeutics PLC ADR BRNSMay 8, 2024 | Behind the Markets (Ad)Fidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.November 17, 2023 | bizjournals.comLab Notes: Vittoria Biotherapeutics raises $15M; Madrigal adds to C-suiteNovember 16, 2023 | morningstar.comIovance Biotherapeutics Inc IOVANovember 9, 2023 | morningstar.comSAB Biotherapeutics Inc SABSOctober 30, 2023 | investing.comCalidi Biotherapeutics Inc (CLDI)September 12, 2023 | msn.comStealth BioTherapeutics achieves target enrolment in PMM therapy trialSeptember 11, 2023 | benzinga.comStealth BioTherapeutics Completes Target Enrollment in Global Phase 3 NuPOWER Trial in Patients with Primary Mitochondrial MyopathySeptember 6, 2023 | bizjournals.comAs Needham biotech struggles with FDA, patients with an ultra-rare disease are waitingJune 2, 2023 | news.yahoo.comB-2 stealth bombers to return to flight after 5-month delayMay 16, 2023 | dailymail.co.ukWealth with stealthMarch 27, 2023 | marketwatch.comGlobal Mitochondrial Myopathy Diagnosis & Treatment Market Size by Type (itochondrial Myopathy Diagnosis) Forecast from 2023 to 2028February 25, 2023 | techcrunch.comChain Reaction raises $70M, emerges from stealth to launch chips designed to compute encrypted dataFebruary 19, 2023 | finance.yahoo.comWill Roper's Istari, Inc. emerges from stealth mode to transform digital engineering and accelerate Industry 4.0November 16, 2022 | finance.yahoo.comStealth BioTherapeutics Corp Announces Completion of MergerNovember 1, 2022 | finance.yahoo.comStealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)October 27, 2022 | news.yahoo.comAs Trump Org trial looms, lawyers to look out for 'stealth jurors'October 7, 2022 | finance.yahoo.comStealth BioTherapeutics Corp to Hold Extraordinary General Meeting of ShareholdersSeptember 15, 2022 | finance.yahoo.comStealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease EventsAugust 5, 2022 | msn.comShort Volatility Alert: Stealth BioTherapeutics CorpSee More Headlines Receive MITO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stealth BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2021Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MITO CUSIPN/A CIK1696396 Webwww.stealthbt.com Phone617-600-6888FaxN/AEmployees29Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,530,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-142.81% Debt Debt-to-Equity RatioN/A Current Ratio3.68 Quick Ratio3.68 Sales & Book Value Annual Sales$21.09 million Price / Sales1.12 Cash FlowN/A Price / Cash FlowN/A Book Value($0.79) per share Price / Book-0.41Miscellaneous Outstanding Shares73,552,000Free FloatN/AMarket Cap$23.54 million OptionableNot Optionable Beta1.46 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMs. Irene P. McCarthy J.D. (Age 57)Pres ,CEO, Sec. & Director Mr. Henry HessChief Legal CounselDr. Ben R. Bronstein M.D. (Age 72)Chief Medical Officer Mr. Brian HotchkissVP of Bus. Devel. & StrategyKey CompetitorsLisata TherapeuticsNASDAQ:LSTATherapeuticsMDNASDAQ:TXMDLumos PharmaNASDAQ:LUMOBullfrog AINASDAQ:BFRGCytoMed TherapeuticsNASDAQ:GDTCView All Competitors MITO Stock Analysis - Frequently Asked Questions How were Stealth BioTherapeutics' earnings last quarter? Stealth BioTherapeutics Corp (NASDAQ:MITO) issued its quarterly earnings results on Thursday, August, 5th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.01. What other stocks do shareholders of Stealth BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stealth BioTherapeutics investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Acasti Pharma (ACST), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Miragen Therapeutics (MGEN), Matinas BioPharma (MTNB), Soleno Therapeutics (SLNO) and Arbutus Biopharma (ABUS). When did Stealth BioTherapeutics IPO? Stealth BioTherapeutics (MITO) raised $81 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets served as the underwriters for the IPO and Nomura was co-manager. This page (NASDAQ:MITO) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stealth BioTherapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.